Compare · ELAB vs NVO
ELAB vs NVO
Side-by-side comparison of PMGC Holdings Inc. (ELAB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELAB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.38B, about 29403.4x ELAB ($6.4M).
- Over the past year, ELAB is down 99.2% and NVO is down 45.4% - NVO leads by 53.8 points.
- ELAB has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for ELAB).
- Company
- PMGC Holdings Inc.
- Novo Nordisk A/S
- Price
- $1.40-1.41%
- $43.34+2.71%
- Market cap
- $6.4M
- $188.38B
- 1M return
- -25.33%
- -6.59%
- 1Y return
- -99.22%
- -45.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 11
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELAB
- PMGC Holdings Highlights Advanced Precision Manufacturing Capabilities Supporting Space Exploration Supply Chains
- PMGC Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- NorthStrive Defense Tech Executes Binding Agreement to Acquire Exclusive License to Patented Multi-Domain Drone Payload Technology for Defense, Aerospace and Maritime Applications
- PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 4 filed by Chief Executive Officer Bensler Graydon
- SEC Form 4 filed by Director Parry Jeffrey
- SEC Form 4 filed by Director Kovalyov George
- SEC Form 4 filed by Director Daley Juliana
- SEC Form 4 filed by Director Braeden Lichti
- PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care